You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 207641 - 207650 of 207731 results
  1. FY 2023 SBIR TOPIC 402 PHASE II.ENHANCE THE PERFORMANCE OF THE AI FOR LYMPH NODE DETECTION, SEGMENTATION AND MEASUREMENTS AND DEVELOP ADDITIONAL AI MODELS FOR MALIGNANCY CLASSIFICATION LEVERAGING MU

    SBC: CARINA MEDICAL LLC            Topic: 402

    The correct determination of nodal metastatic disease is imperative for patient management in oncology, since the patient’s prognosis and subsequent treatment are inherently linked to the stage of disease. Detection/segmentation of lymph node on imaging is a tedious, highly time-consuming process that is inherently subject to intra-/inter-observer variability. Malignancy classification of the ly ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. ARPA-H SBIR PHASE II TOPIC 4 FOR INTRA-OPERATIVE CONTRAST AGENTS

    SBC: OPTOSURGICAL LLC            Topic: AH04

    The project aims to advance the development of BL-760, a near-infrared contrast agent designed for clear intraoperative identification of bile ducts. This novel dye addresses the significant medical issue of bile duct injury during hepatobiliary surgeries (e.g., cholecystectomy, hepatectomy), impacting over 1 million patients annually. The project plans to produce BL-760 with high quality standard ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. TOPIC 447: DEVELOPMENT AND TESTING OF A NON-INVASIVE CRYO-DEVICE TO PREVENT CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN HANDS AND FEET OF CANCER PATIENTS RECEIVING TAXOL FOR BREAST CANCER.

    SBC: EISANA CORP            Topic: 447

    The objective of this proposal is to develop a prototype device capable of cooling extremities to a level sufficient for prevention of chemotherapy-induced peripheral neuropathy (CIPN). Such a product will enable healthcare providers to make available a solution to prevent the physical pain and reduction in quality of life resulting from CIPN. The following Aims will be completed: (1) design, buil ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. RAPID POINT OF CARE TEST TO SCREEN HUMAN PAPILLOMAVIRUS IN LOW-RESOURCE SETTINGS

    SBC: ZYMERON CORPORATION            Topic: 451

    Cervical cancer caused by human papillomavirus (HPV) is the fourth most common cancer among women worldwide, but it is preventable by screening asymptomatic women before HPV infection progresses to an invasive disease. The screening programs in developed countries use the cytology-based approach (Pap testing) followed by colposcopy, which require a high degree of organization and management. They ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. AWARD SBIR TOPIC #110 PHASE II-MRI MYOCARDIAL BIOPSY SYSTEM

    SBC: TRANSMURAL SYSTEMS LLC            Topic: 110

    Endomyocardial biopsies are performed approximately 10,000 times each year worldwide.The procedure suffers large anatomic sampling error because of no current appropriate image guidance.Endomyocardial biopsy is currently performed without targeting, whether under X-ray or ultrasound guidance.This may account for the known low diagnostic yield and high sampling error.MRI operation affords exquisite ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. UBIQUIBODY PLATFORM FOR TARGETED DEGRADATION OF ONCOGENIC FUSION PROTEINS

    SBC: UBIQUITX INC            Topic: NCICA25

    UbiquiTx is pioneering a novel class of mRNA therapeutics that potently and selectively degrade targets not historically addressable by small-molecule degraders. Ubiquibodies (uAbs) are protein fusions that can bind to a target of interest and tag it for targeted intracellular degradation via the endogenous ubiquitin-proteasome pathway (UPP). These novel molecules promise to fundamentally transfor ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. SBIR CONCEPT AWARD-NANOSPONGE LINKED DCLK1 INHIBITORS FOR THE TARGETED TREATMENT OF CHOLANGIOCARCINOMA

    SBC: DCLK1 LLC            Topic: NCICA23

    The proposed product is designed to meet a high unmet medical need for osteosarcoma (OS), a rare pediatric cancer. OS accounts for 2% of childhood cancers (60% of cases occurring in patients who are 10-20 years of age).(1) OS 5-year survival is 70% for non-metastasized disease, 30% for metastasized primarily as a result of its highly metastatic and drug-resistant nature. Cytotoxic chemotherapy and ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. ENGINEERED MICROBIAL THERAPEUTICS FOR METHIONINE RESTRICTION TREATMENT OF HERITABLE FORMS OF GLIOMA.

    SBC: Petri Bio LLC            Topic: NCICA24

    Systemic methionine levels have long been implicated in cancer disease onset and progression, with changes in cellular metabolism rendering tumor cells sensitive to amino acid deficiencies.Petri Bio, Inc. has developed a novel therapeutic strategy, using microbiome-compatible bacterial strains as expression vectors for metabolic enzymes.The company’s lead product is a live biotherapeutic microbe ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. SBIR INNOVATIVE CONCEPT AWARD (TOPIC- DEVELOPMENT OF DEVICES OR DIAGNOSTICS FOR TREATMENT, DETECTION AND DIAGNOSIS OF PEDIATRIC CANCERS AND/OR RARE CANCERS)

    SBC: GENOMIC EXPRESSION INC            Topic: NCICA29

    The long term objective of this proposal is to improve outcomes for ovarian cancer patients in the frontline setting. Few effective drug treatment options exist for ovarian cancer and other rare cancers whereas 300+ drugs have been approved by the FDA to treat non-rare cancers. Analysis of tumor mRNA gene expression has the potential to identify over expression of approved drug targets, such as HE ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. PURPOSE OF THIS MODIFICATION IS TO EXERCISE THE I-CORP OPTION

    SBC: Nomocan Pharmaceuticals LLC            Topic: NCICA26

    NomoCan Pharmaceuticals is developing a first-in-class humanized monoclonal antibody, NMC-521, against a novel plasma membrane-bound variant of the protein MDM2 as a targeted treatment for cancer with fewer side effects, initially focusing on pancreatic cancer (PC). PC has one of the lowest 5-year survival rates among all cancer types, remaining below 10% for the past 40 years, indicating a need f ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government